Tiago Biachi De Castria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tiago Biachi De Castria has a total of 310 co-authors. Here are the top co-authors by number of shared publications:
- Arijh Elzein
11Department of Pharmacology, Weill Cornell Medicine Graduate School of Medical Sciences, New York, New York
101 shared publications - David B. Solit
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
101 shared publications - David Herman Ilson
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY
101 shared publications - Fiona Socolow
Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
101 shared publications - Geoffrey Yuyat Ku
Memorial Sloan Kettering Cancer Center
101 shared publications - Henry Walch
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
101 shared publications
Latest Publications
- Open Access
Transcriptomic Profiling and Demographic Analysis of Appalachian Patients with Pancreatic Ductal Adenocarcinoma using the Purity Independent Subtyping of Tumors (PurIST) Classifier
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with poor prognosis. A transcriptomic-based algorithm called Purity Independent Subtyping of Tumors (PurIST) relies on expression profiling of a defined set of genes to stratify PDAC into classical and basal-like molecular subtypes and assigns a confidence level to the subtypes as either “strong,” “likely,” or “lean.” In this study, we apply PurIST to Appalachian and non-Appalachian patient cohorts and assess demographic variables between groups that may influence treatment outcomes. PATIENTS AND METHODS: This 13-site study includes 780 PDAC patients. Patients were divided into Appalachian and non-Appalachian cohorts according to Appalachian Regional Commission guidelines, and differences in PurIST classification, tobacco use, and alcohol use were analyzed. RESULTS: Individuals from Appalachian regions were more likely to receive a subtype classification from PurIST with “strong” confidence as opposed to “likely” or “lean” ( P =0.0175; odds ratio=1.66). We did not observe any significant difference between basal and classical subtype classification in Appalachia ( P =0.1457), yet an exploratory analysis showed that individuals aged ≥85 were significantly more likely to have basal-like tumor classifications ( P =0.005817; odds ratio=3.79). Appalachian patients were more likely to have a history of smoking (59.6% vs 49.9%; P =0.01756) and less likely to report alcohol consumption (50.5% vs 65.6%; P =0.000229). CONCLUSION: We conducted the largest comparison of the PurIST algorithm in Appalachia to date and found PurIST is more likely to have higher confidence in molecular subtype classifications for Appalachian PDAC tumors compared to non-Appalachian tumors. If PurIST is to be considered as a prognostic or decision-making tool for PDAC patients, we must account for variability in different populations and model the likelihood that tumors will have a strong molecular signature.
Open AccessTranscriptomic Profiling and Demographic Analysis of Appalachian Patients with Pancreatic Ductal Adenocarcinoma using the Purity Independent Subtyping of Tumors (PurIST) Classifier
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with poor prognosis. A transcriptomic-based algorithm called Purity Independent Subtyping of Tumors (PurIST) relies on expression profiling of a defined set of genes to stratify PDAC into classical and basal-like molecular subtypes and assigns a confidence level to the subtypes as either “strong,” “likely,” or “lean.” In this study, we apply PurIST to Appalachian and non-Appalachian patient cohorts and assess demographic variables between groups that may influence treatment outcomes. PATIENTS AND METHODS: This 13-site study includes 780 PDAC patients. Patients were divided into Appalachian and non-Appalachian cohorts according to Appalachian Regional Commission guidelines, and differences in PurIST classification, tobacco use, and alcohol use were analyzed. RESULTS: Individuals from Appalachian regions were more likely to receive a subtype classification from PurIST with “strong” confidence as opposed to “likely” or “lean” ( P =0.0175; odds ratio=1.66). We did not observe any significant difference between basal and classical subtype classification in Appalachia ( P =0.1457), yet an exploratory analysis showed that individuals aged ≥85 were significantly more likely to have basal-like tumor classifications ( P =0.005817; odds ratio=3.79). Appalachian patients were more likely to have a history of smoking (59.6% vs 49.9%; P =0.01756) and less likely to report alcohol consumption (50.5% vs 65.6%; P =0.000229). CONCLUSION: We conducted the largest comparison of the PurIST algorithm in Appalachia to date and found PurIST is more likely to have higher confidence in molecular subtype classifications for Appalachian PDAC tumors compared to non-Appalachian tumors. If PurIST is to be considered as a prognostic or decision-making tool for PDAC patients, we must account for variability in different populations and model the likelihood that tumors will have a strong molecular signature.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (6) , e2500807
Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) ranks third in cancer-related deaths. Although national guidelines recommend germline multigene panel testing (MGPT) for all patients with PDAC, only 6%-19% undergo testing, mostly due to under-referral and genetic counselor shortages. We evaluated a coordinator-led and digitally supported workflow designed to increase access to pretest education, improve MGPT uptake, and reduce turnaround time (TAT) for patients newly diagnosed with PDAC at our center. METHODS: Through the Genetic Information for Treatment Decisions (GIFTD) Initiative, a Genetic Risk Education Coordinator (GREC) served as a liaison between providers, genetic counselors, and patients. Subsequently, we partnered with Nest Genomics to develop the GIFTD Partially Automated Nest Copilot (G-PANC), a digital tool that collects cancer history, delivers genetic education, and assesses MGPT interest before coordinator follow-up. Outcomes included genetic education completion, MGPT uptake, and TAT across sequential phases (baseline, GREC-only, and G-PANC [GREC+ Nest Copilot]). RESULTS: Over 1 year, 354 patients with PDAC were invited to access G-PANC; 73% activated accounts, 80% completed education, and 63% expressed MGPT interest. Among those completing education, 86% engaged with the GREC, and 81% consented to testing, including 15 initially uninterested patients. Of the 127 patients tested, 13% had pathogenic variants. Compared with a baseline/traditional workflow, the GREC-only phase was associated with increased MGPT uptake (43% to 80%) and reduced TAT (54 to 30 days). During the subsequent G-PANC phase, testing uptake remained high (77%) and TAT further decreased to 22 days. CONCLUSION: A coordinator-led workflow substantially increased MGPT uptake and reduced TAT. Digital education integration was feasible, maintained high testing rates, and reduced TAT. Prospective evaluation will clarify the independent contributions of digital automation.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (6) , e2500807
Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) ranks third in cancer-related deaths. Although national guidelines recommend germline multigene panel testing (MGPT) for all patients with PDAC, only 6%-19% undergo testing, mostly due to under-referral and genetic counselor shortages. We evaluated a coordinator-led and digitally supported workflow designed to increase access to pretest education, improve MGPT uptake, and reduce turnaround time (TAT) for patients newly diagnosed with PDAC at our center. METHODS: Through the Genetic Information for Treatment Decisions (GIFTD) Initiative, a Genetic Risk Education Coordinator (GREC) served as a liaison between providers, genetic counselors, and patients. Subsequently, we partnered with Nest Genomics to develop the GIFTD Partially Automated Nest Copilot (G-PANC), a digital tool that collects cancer history, delivers genetic education, and assesses MGPT interest before coordinator follow-up. Outcomes included genetic education completion, MGPT uptake, and TAT across sequential phases (baseline, GREC-only, and G-PANC [GREC+ Nest Copilot]). RESULTS: Over 1 year, 354 patients with PDAC were invited to access G-PANC; 73% activated accounts, 80% completed education, and 63% expressed MGPT interest. Among those completing education, 86% engaged with the GREC, and 81% consented to testing, including 15 initially uninterested patients. Of the 127 patients tested, 13% had pathogenic variants. Compared with a baseline/traditional workflow, the GREC-only phase was associated with increased MGPT uptake (43% to 80%) and reduced TAT (54 to 30 days). During the subsequent G-PANC phase, testing uptake remained high (77%) and TAT further decreased to 22 days. CONCLUSION: A coordinator-led workflow substantially increased MGPT uptake and reduced TAT. Digital education integration was feasible, maintained high testing rates, and reduced TAT. Prospective evaluation will clarify the independent contributions of digital automation.
- Open Access
- 18 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma
Background Pancreatic ductal adenocarcinoma is projected to become the second leading cause of cancer-related deaths by 2040, with the highest disease burden expected amongst Non-Hispanic Black patients. One of the most significant predictors of poor outcomes is the presence of cancer-associated cachexia (CCa). Yet, race- and ethnicity-specific biomarkers for early CCa diagnosis are lacking. Methods We evaluated a panel of candidate biomarkers of CCa in a diverse cohort of patients with pre-treatment serum using multiplex ELISA-based methods. Results We find that growth/differentiation factor-15 (GDF-15) is associated with cachexia severity, is superior to standard biomarkers at classifying cachexia, and differentiates between non-cachexia and pre-cachexia status, but only among Hispanic/Latinx and non-Hispanic White participants. Furthermore, high GDF-15 levels at diagnosis are associated with a greater weight loss from 3.3% (95%CI = −0.14–6.7) to 8.0% (CI = 5.9–10.1) over the 6 months post-diagnosis. Finally, both ENA-78/CXCL5 and GRO-α/CXCL1 are elevated in non-Hispanic Black individuals in a disease-independent manner (P < 0.001 for both analytes). Conclusions GDF-15 may be a potential biomarker for “pre-cachexia” in the non-Hispanic White and the Hispanic population, but not non-Hispanic Black individuals. These findings underscore the unmet need to enroll non-Hispanic Black participants in clinical trials for CCa.
- 18 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessRace-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma
Background Pancreatic ductal adenocarcinoma is projected to become the second leading cause of cancer-related deaths by 2040, with the highest disease burden expected amongst Non-Hispanic Black patients. One of the most significant predictors of poor outcomes is the presence of cancer-associated cachexia (CCa). Yet, race- and ethnicity-specific biomarkers for early CCa diagnosis are lacking. Methods We evaluated a panel of candidate biomarkers of CCa in a diverse cohort of patients with pre-treatment serum using multiplex ELISA-based methods. Results We find that growth/differentiation factor-15 (GDF-15) is associated with cachexia severity, is superior to standard biomarkers at classifying cachexia, and differentiates between non-cachexia and pre-cachexia status, but only among Hispanic/Latinx and non-Hispanic White participants. Furthermore, high GDF-15 levels at diagnosis are associated with a greater weight loss from 3.3% (95%CI = −0.14–6.7) to 8.0% (CI = 5.9–10.1) over the 6 months post-diagnosis. Finally, both ENA-78/CXCL5 and GRO-α/CXCL1 are elevated in non-Hispanic Black individuals in a disease-independent manner (P < 0.001 for both analytes). Conclusions GDF-15 may be a potential biomarker for “pre-cachexia” in the non-Hispanic White and the Hispanic population, but not non-Hispanic Black individuals. These findings underscore the unmet need to enroll non-Hispanic Black participants in clinical trials for CCa.
- 16 December 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (5) , 699-706
Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis
Hepatocellular carcinoma (HCC) relapse remains high after curative-intent treatment due to occult minimal residual disease. Circulating tumour DNA (ctDNA) has emerged as a noninvasive biomarker. Systematic search of MEDLINE, EMBASE and the Cochrane Library up to November 2024 identified studies evaluating plasma ctDNA in non-metastatic HCC patients undergoing curative-intent treatment. Hazard ratios (HRs) and 95% confidence intervals (CIs) for recurrence-free survival (RFS) and overall survival (OS) were pooled using random-effects models; sensitivity and specificity for predicting recurrence were summarised. Ten retrospective studies (n = 793) met inclusion criteria. Postoperative ctDNA positivity was associated with shorter RFS (HR 4.48; 95% CI 2.56–7.82; I² = 78%; p < 0.001) and worse OS (HR 2.99; 95% CI 1.94–4.61; I² = 47%; p < 0.001). Baseline ctDNA detection predicted reduced RFS (HR 3.54; 95% CI 1.97–6.38; I² = 35%; p < 0.001). Sensitivity ranged 33–82% and specificity 41–100%, reflecting methodological heterogeneity. Leave-one-out analyses confirmed robustness. Plasma ctDNA is a potent prognostic marker of recurrence and survival in non-metastatic HCC. Prospective trials incorporating ctDNA could optimise postoperative surveillance and guide adjuvant therapy selection.
- 16 December 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (5) , 699-706
Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis
Hepatocellular carcinoma (HCC) relapse remains high after curative-intent treatment due to occult minimal residual disease. Circulating tumour DNA (ctDNA) has emerged as a noninvasive biomarker. Systematic search of MEDLINE, EMBASE and the Cochrane Library up to November 2024 identified studies evaluating plasma ctDNA in non-metastatic HCC patients undergoing curative-intent treatment. Hazard ratios (HRs) and 95% confidence intervals (CIs) for recurrence-free survival (RFS) and overall survival (OS) were pooled using random-effects models; sensitivity and specificity for predicting recurrence were summarised. Ten retrospective studies (n = 793) met inclusion criteria. Postoperative ctDNA positivity was associated with shorter RFS (HR 4.48; 95% CI 2.56–7.82; I² = 78%; p < 0.001) and worse OS (HR 2.99; 95% CI 1.94–4.61; I² = 47%; p < 0.001). Baseline ctDNA detection predicted reduced RFS (HR 3.54; 95% CI 1.97–6.38; I² = 35%; p < 0.001). Sensitivity ranged 33–82% and specificity 41–100%, reflecting methodological heterogeneity. Leave-one-out analyses confirmed robustness. Plasma ctDNA is a potent prognostic marker of recurrence and survival in non-metastatic HCC. Prospective trials incorporating ctDNA could optimise postoperative surveillance and guide adjuvant therapy selection.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Early change in tumor-matched maxVAF in patients who received induction trastuzumab and pembrolizumab stratified by 6 month PFS (n=16 evaluable).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Early change in tumor-matched maxVAF in patients who received induction trastuzumab and pembrolizumab stratified by 6 month PFS (n=16 evaluable).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Plasma ctDNA Alterations by Source.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Plasma ctDNA Alterations by Source.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Univariable Cox Proportional Hazard for PFS in HER2-targeted retrospective cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Univariable Cox Proportional Hazard for PFS in HER2-targeted retrospective cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Baseline biopsies from a patient demonstrating significant intra-patient heterogeneity with diffusely HER2+ and PD-L1– primary tumor and HER2– but PD-L1 CPS 100 retroperitoneal lymph node with neuroendocrine differentiation.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Baseline biopsies from a patient demonstrating significant intra-patient heterogeneity with diffusely HER2+ and PD-L1– primary tumor and HER2– but PD-L1 CPS 100 retroperitoneal lymph node with neuroendocrine differentiation.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Survival and response in patients receiving trastuzumab/chemotherapy + PD-1 inhibition on- or off-protocol (n=66). a, Progression-free survival and objective response rate by cohort. b, Overall survival by cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Survival and response in patients receiving trastuzumab/chemotherapy + PD-1 inhibition on- or off-protocol (n=66). a, Progression-free survival and objective response rate by cohort. b, Overall survival by cohort.